ENDOMETRIOID OVARIAN CANCER
Clinical trials for ENDOMETRIOID OVARIAN CANCER explained in plain language.
Never miss a new study
Get alerted when new ENDOMETRIOID OVARIAN CANCER trials appear
Sign up with your email to follow new studies for ENDOMETRIOID OVARIAN CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for hard-to-treat ovarian cancer: targeted drug enters phase 2 trial
Disease control Recruiting nowThis study tests a new drug called TORL-1-23 in women with advanced ovarian cancer that no longer responds to platinum-based chemotherapy. The drug targets a protein called claudin 6 found on cancer cells. About 230 women will receive the drug to see if it shrinks tumors and how …
Matched conditions: ENDOMETRIOID OVARIAN CANCER
Phase: PHASE2 • Sponsor: TORL Biotherapeutics, LLC • Aim: Disease control
Last updated Jun 22, 2026 12:09 UTC
-
New hope for Hard-to-Treat ovarian cancer: drug combo enters human testing
Disease control Recruiting nowThis early-phase study tests whether combining two drugs, Cirtuvivint and Olaparib, is safe for women with ovarian cancer that no longer responds to platinum chemotherapy. About 50 participants will take the medications on different schedules and visit the clinic regularly for ch…
Matched conditions: ENDOMETRIOID OVARIAN CANCER
Phase: PHASE1 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 18, 2026 11:50 UTC
-
Virus therapy shows promise against tough ovarian cancer in new trial
Disease control Recruiting nowThis study tests a new treatment called Olvi-Vec, a virus that targets cancer cells, followed by standard chemotherapy and bevacizumab, in women with ovarian cancer that no longer responds to platinum-based drugs. About 186 participants will receive either the virus combination o…
Matched conditions: ENDOMETRIOID OVARIAN CANCER
Phase: PHASE3 • Sponsor: Genelux Corporation • Aim: Disease control
Last updated Jun 17, 2026 12:08 UTC